Samsung Biologics pitches end-to-end CDMO services as Japan demand surges - Korea Biomedical Review
Samsung Biologics pitches end-to-end CDMO services as Japan demand surges Korea Biomedical Review
Related discussion groups
No group discusses this yet. Start a discussion group and attach this story.
More news about Japan
- Japan’s small-cap cull is an opportunity for AI fundsFinding needles amid haystacks is a task for AI
- Japan was never normal — and it’s not going to be nowThe LDP needs to rethink decades of small-business policy for an era of far bigger problems
- Japan beer giants raided over suspicions they colluded to set the price of beveragesInvestigators probe Asahi, Kirin, Suntory and Sapporo breweries – which together control more than 90% of Japan’s beer marketJapanese authorities have raided the country’s four biggest breweries ov...
- Japan 30-Year Bond Sale Sees Firmer Demand Than 12-Month AverageJapan’s 30-year government bond auction drew stronger demand than its 12-month average as elevated yields attracted investors.
- Japan and Ukraine further ties as Tokyo weighs unprecedented security linkup - The Japan TimesJapan and Ukraine further ties as Tokyo weighs unprecedented security linkup The Japan Times
- Japanese Stocks Fall as Inflation Fears Hit Cyclical SharesJapanese stocks fell for a second day, tracking a Wall Street selloff as persistently high oil prices revived inflation concerns and weighed on equities near record highs.
- Japan explores ‘ownership’ of nuclear submarines as regional rivalries worsenJapan is expected to float the idea of acquiring a fleet of nuclear-powered submarines in revised security documents to be released later this year, with analysts suggesting that Tokyo’s initial ai...
- Verstappen revival to be put to the test in steamy Singapore - Japan TodayVerstappen revival to be put to the test in steamy Singapore Japan Today